VIR - Vir Biotechnology Inc Stock Price, Fair Value and News

9.79USD+0.35 (+3.71%)Market Closed

Market Summary

USD9.79+0.35

Market Closed

3.71%

VIR Alerts

1 major insider sales recently.

Big fall in Revenue (Y/Y)
Big jump in Earnings (Y/Y)
Losses in recent quarter

VIR Stock Price

View Fullscreen

VIR RSI Chart

VIR Valuation

Market Cap

1.3B

Price/Earnings (Trailing)

-2.47

Price/Sales (Trailing)

16.73

EV/EBITDA

-2.16

Price/Free Cashflow

-1.71

VIR Price/Sales (Trailing)

VIR Profitability

Operating Margin

98.85%

EBT Margin

-690.97%

Return on Equity

-34.86%

Return on Assets

-30.07%

Free Cashflow Yield

-58.48%

VIR Fundamentals

VIR Revenue

Revenue (TTM)

79.6M

Rev. Growth (Yr)

-10.45%

Rev. Growth (Qtr)

235.83%

VIR Earnings

Earnings (TTM)

-539.4M

Earnings Growth (Yr)

53.69%

Earnings Growth (Qtr)

43.71%

Breaking Down VIR Revenue

Last 7 days

-4.2%

Last 30 days

9.1%

Last 90 days

10.6%

Trailing 12 Months

-60.3%

How does VIR drawdown profile look like?

VIR Financial Health

Current Ratio

12.9

VIR Investor Care

Shares Dilution (1Y)

1.55%

Diluted EPS (TTM)

-4.01

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	79.6M	0	0	0
2023	1.1B	490.7M	118.8M	86.2M
2022	2.3B	2.1B	1.9B	1.6B
2021	331.1M	585.9M	840.7M	1.1B
2020	10.1M	75.1M	75.6M	76.4M
2019	11.9M	11.7M	10.2M	8.1M
2018	4.7M	6.7M	8.7M	10.7M
2017	0	0	0	2.7M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Vir Biotechnology Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 03, 2024	de backer marianne	sold	-690,365	9.4577	-72,995	chief executive officer
Apr 01, 2024	hanly ann m.	sold	-27,251	10.052	-2,711	evp & chief technology officer
Mar 27, 2024	lee sung	sold	-59,404	9.8875	-6,008	evp & chief financial officer
Feb 26, 2024	scangos george a	sold	-206,522	11.6534	-17,722	-
Feb 22, 2024	hanly ann m.	acquired	-	-	32,500	evp & chief technology officer
Feb 22, 2024	pang phillip	sold	-146,344	10.0456	-14,568	evp & chief medical officer
Feb 22, 2024	scangos george a	sold	-100,737	10.0456	-10,028	-
Feb 22, 2024	lee sung	acquired	-	-	40,000	evp & chief financial officer
Feb 22, 2024	hanly ann m.	sold	-123,521	10.0456	-12,296	evp & chief technology officer
Feb 22, 2024	de backer marianne	acquired	-	-	175,000	chief executive officer

Which funds bought or sold VIR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 10, 2024	JPMORGAN CHASE & CO	added	104	2,413,630	4,692,690	-%
May 10, 2024	LPL Financial LLC	new	-	311,335	311,335	-%
May 10, 2024	Pinnacle Wealth Planning Services, Inc.	unchanged	-	796	115,259	0.02%
May 10, 2024	Y-Intercept (Hong Kong) Ltd	new	-	185,582	185,582	0.01%
May 10, 2024	CORNERCAP INVESTMENT COUNSEL INC	added	82.81	105,414	230,782	0.04%
May 10, 2024	Vontobel Holding Ltd.	reduced	-1.45	-3,658	475,188	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	added	14.49	40,021	301,833	-%
May 10, 2024	Covestor Ltd	reduced	-7.69	-	-	-%
May 10, 2024	CITIGROUP INC	added	445	9,320,950	11,393,500	0.01%
May 10, 2024	ACADIAN ASSET MANAGEMENT LLC	sold off	-100	-27,000	-	-%

Are Funds Buying or Selling VIR?

Are funds buying VIR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own VIR

No. of Funds

Unveiling Vir Biotechnology Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	sb investment advisers (uk) ltd	12.4%	16,684,041	SC 13G/A
Feb 13, 2024	vanguard group inc	9.14%	12,297,139	SC 13G/A
Jan 24, 2024	state street corp	5.14%	6,912,082	SC 13G
Jan 23, 2024	blackrock inc.	12.5%	16,864,579	SC 13G/A
Feb 14, 2023	softbank vision fund (aiv m1) l.p.	15.2%	20,259,535	SC 13G/A
Feb 09, 2023	vanguard group inc	7.58%	10,094,501	SC 13G/A
Jan 24, 2023	blackrock inc.	10.6%	14,136,628	SC 13G/A
Sep 13, 2022	arch venture fund ix, l.p.	9.7%	12,916,663	SC 13D/A
Sep 08, 2022	blackrock inc.	10.1%	13,384,194	SC 13G
May 10, 2022	arch venture fund ix, l.p.	14.5%	18,916,663	SC 13D/A

Recent SEC filings of Vir Biotechnology Inc

View All Filings

Date Filed	Form Type	Document
May 03, 2024	10-Q	Quarterly Report
May 02, 2024	8-K	Current Report
Apr 19, 2024	ARS	ARS
Apr 19, 2024	DEF 14A	DEF 14A
Apr 19, 2024	DEFA14A	DEFA14A
Apr 18, 2024	8-K	Current Report
Apr 04, 2024	144	Notice of Insider Sale Intent
Apr 04, 2024	4	Insider Trading
Apr 03, 2024	144	Notice of Insider Sale Intent
Apr 02, 2024	4	Insider Trading

Peers (Alternatives to Vir Biotechnology Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.2B	6.8B	19.54%	-2.80%	-8.07	7.03	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.0B	2.0B	0.98%	-26.98%	-57.12	9.47	75.20%	68.82%
BMRN	15.3B	2.5B	-12.72%	-14.31%	74.39	6.18	13.74%	186.89%
INCY	12.9B	3.8B	6.98%	-11.75%	17.35	3.43	8.58%	129.81%
MID-CAP
BBIO	5.3B	107.9M	6.22%	110.41%	-9.76	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-16.95%	-51.10%	-12.51	9.96	394.93%	39.61%
AXSM	3.6B	251.0M	9.36%	-4.29%	-12.12	14.31	73.58%	-86.73%
ARWR	2.7B	240.7M	-10.69%	-43.90%	-5.82	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-11.38%	-29.25%	-1.5K	3.08	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	6.64%	20.67%	29.44	4.66	60.38%	-34.49%
NVAX	1.8B	996.6M	206.31%	55.15%	-4.62	1.85	-26.66%	65.49%
CRBP	458.7M	881.7K	5.07%	336.18%	-13.59	481.06	-77.61%	33.36%
INO	294.6M	4.9M	3.08%	29.79%	-2.36	60.54	-54.97%	48.23%
IBIO	15.6M	2.1M	-10.40%	79.21%	-0.67	7.61	-13.45%	69.54%

Vir Biotechnology Inc News

Latest updates

Vir Biotechnology Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	235.8%	56,376,000	16,787,000	2,639,000	3,797,000	62,957,000	49,410,000	374,557,000	803,508,000	1,232,459,000	812,747,000	103,616,000	177,068,000	89,401,000	1,734,000	1,928,000	66,988,000	5,718,000	980,000	1,403,000	2,047,000	3,661,000
Cost Of Revenue	-92.6%	59,000	798,000	38,000	22,000	1,907,000	5,996,000	22,253,000	27,921,000	90,149,000	56,881,000	7,836,000	1,144,000	-	-	-	-	-	-	-	-	-
Costs and Expenses	-12.4%	136,457,000	155,803,000	189,371,000	218,983,000	206,328,000	199,912,000	179,593,000	184,593,000	218,631,000	240,999,000	157,001,000	116,051,000	160,609,000	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	157,001,000	116,051,000	160,609,000	110,138,000	89,543,000	96,039,000	77,628,000	64,739,000	49,083,000	37,817,000	34,431,000
S&GA Expenses	-15.8%	36,273,000	43,090,000	41,080,000	47,101,000	46,778,000	38,743,000	43,174,000	41,590,000	38,255,000	55,777,000	50,496,000	28,781,000	25,739,000	23,043,000	18,859,000	16,386,000	12,649,000	11,808,000	9,220,000	8,011,000	8,559,000
R&D Expenses	-10.5%	100,125,000	111,915,000	148,253,000	171,860,000	157,643,000	155,173,000	114,166,000	115,082,000	90,227,000	128,341,000	98,669,000	86,126,000	134,870,000	87,095,000	70,684,000	79,653,000	64,979,000	52,931,500	39,863,000	29,805,000	25,872,000
EBITDA Margin	5.5%	-6.68	-7.07	-5.41	-0.53	-0.29	0.47	0.79	0.65	0.71	0.51	-0.11	-0.50	-	-	-	-	-	-	-	-	-
Income Taxes	105.8%	276,000	-4,784,000	-3,213,000	-2,848,000	-2,232,000	-50,035,000	42,420,000	-157,228,000	403,286,000	20,635,000	334,000	53,000	196,000	-30,000	22,000	46,000	16,000	149,000	-13,000	19,000	-
Earnings Before Taxes	46.2%	-65,000,000	-120,757,000	-166,626,000	-197,623,000	-143,188,000	-151,638,000	217,732,000	-233,721,000	921,907,000	545,889,000	110,762,000	61,866,000	-168,715,000	-105,679,000	-84,587,000	-31,121,000	-77,224,000	-63,622,500	-48,327,000	-33,909,000	-28,670,000
EBT Margin	5.2%	-6.91	-7.29	-5.55	-0.56	-0.30	0.47	0.78	0.64	0.71	0.50	-0.12	-0.51	-	-	-	-	-	-	-	-	-
Net Income	43.7%	-65,276,000	-115,973,000	-163,413,000	-194,775,000	-140,956,000	-101,603,000	175,312,000	-76,493,000	518,621,000	525,254,000	110,428,000	61,813,000	-168,911,000	-105,649,000	-84,609,000	-31,167,000	-77,240,000	-63,771,000	-48,314,000	-33,928,000	-28,670,000
Net Income Margin	5.1%	-6.78	-7.14	-5.06	-0.53	-0.14	0.32	0.62	0.52	0.52	0.48	-0.12	-0.51	-	-	-	-	-	-	-	-	-
Free Cashflow	-1.6%	-111,262,000	-109,462,000	-159,543,000	-398,704,000	-132,649,000	22,552,000	98,909,000	939,538,000	534,248,000	-5,372,000	-111,819,000	137,981,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																				(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2018Q4
Assets	-6.5%	1,794	1,919	2,045	2,244	2,666	2,802	2,696	2,619	2,887	1,954	1,210	1,058	1,136	919	943	672	477	512	423	192
Current Assets	-23.6%	1,213	1,588	1,769	1,946	2,359	2,519	2,414	2,288	2,568	1,563	1,066	862	993	772	850	579	378	403	338	118
Cash Equivalents	-25.3%	180	242	452	667	825	849	964	1,505	812	348	715	742	521	451	463	372	168	123	94.00	59.00
Net PPE	-3.7%	92.00	96.00	99.00	104	104	106	100	85.00	66.00	43.00	27.00	20.00	17.00	18.00	17.00	16.00	16.00	16.00	15.00	12.00
Goodwill	0%	17.00	17.00	17.00	17.00	17.00	17.00	17.00	17.00	17.00	17.00	17.00	17.00	17.00	17.00	17.00	17.00	17.00	17.00	17.00	17.00
Liabilities	-25.0%	247	329	370	434	695	724	546	667	886	522	334	320	485	202	131	108	97.00	88.00	67.00	62.00
Current Liabilities	-46.4%	94.00	175	165	226	485	511	308	478	702	341	234	146	361	99.00	77.00	55.00	56.00	59.00	44.00	40.00
Shareholder's Equity	-2.7%	1,547	1,590	1,675	1,810	1,971	2,078	2,150	1,952	2,001	1,432	876	737	651	717	812	564	380	424	-	-
Retained Earnings	-27.5%	-303	-237	-121	42.00	236	377	479	304	380	-138	-663	774	-836	-667	-561	-476	-445	-368	-304	-193
Additional Paid-In Capital	1.3%	1,853	1,829	1,799	1,772	1,738	1,710	1,683	1,656	1,626	1,572	1,541	1,513	1,488	1,385	1,374	1,041	826	793	24.00	15.00
Shares Outstanding	0.8%	136	135	134	134	134	133	132	132	132	130	130	130	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	0.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	1,800	-	-	-	2,000	-	-	-	2,700	-	-	-	2,300	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-1.4%	-109,390	-107,927	-155,829	-389,247	-125,782	35,126	117,902	960,136	550,089	7,695	-105,813	140,058	-89,529	-82,052	-49,841	-10,639	-48,409	-38,885	-36,955	-24,303	-29,489
Share Based Compensation	-16.0%	23,757	28,272	26,944	30,619	25,481	24,865	24,814	27,099	25,304	24,371	22,944	20,998	15,471	10,301	8,582	5,750	2,967	2,679	2,188	1,399	2,453
Cashflow From Investing	127.1%	28,420	-104,811	-58,954	230,315	98,079	-153,135	-662,605	-272,329	-105,392	-377,582	73,859	75,375	87,534	60,713	-185,379	10,585	104,219	-73,769	47,292	44,483	-274,164
Cashflow From Financing	-91.0%	152	1,680	277	3,179	2,344	2,011	1,985	3,080	27,685	5,670	3,629	3,529	87,503	-259	324,308	205,340	85.00	130,100	1,732	3.00	317,409

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

VIR Income Statement

2024-03-31

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Total revenues	$ 56,376	$ 62,957
Operating expenses:
Cost of revenue	59	1,907
Research and development	100,125	157,643
Selling, general and administrative	36,273	46,778
Total operating expenses	136,457	206,328
Loss from operations	(80,081)	(143,371)
Other income:
Change in fair value of equity investments	(5,915)	(13,103)
Interest income	21,283	21,307
Other expense, net	(287)	(8,021)
Total other income	15,081	183
Loss before (provision for) benefit from income taxes	(65,000)	(143,188)
(Provision for) benefit from income taxes	(276)	2,232
Net loss	(65,276)	(140,956)
Net loss attributable to noncontrolling interest	0	(56)
Net loss attributable to Vir	$ (65,276)	$ (140,900)
Net loss per share attributable to Vir, basic (in USD per share)	$ (0.48)	$ (1.06)
Net loss per share attributable to Vir, diluted (in USD per share)	$ (0.48)	$ (1.06)
Weighted-average shares outstanding, basic (in shares)	135,280,648	133,552,839
Weighted-average share outstanding, diluted (in shares)	135,280,648	133,552,839
Collaboration revenue
Revenues:
Total revenues	$ (987)	$ 46,574
Contract revenue
Revenues:
Total revenues	52,191	138
Grant revenue
Revenues:
Total revenues	$ 5,172	$ 16,245

VIR Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
CURRENT ASSETS:
Cash and cash equivalents	$ 160,711	$ 241,576
Short-term investments	985,125	1,270,980
Restricted cash and cash equivalents, current	13,335	13,268
Equity investments	3,927	9,853
Prepaid expenses and other current assets	49,999	52,549
Total current assets	1,213,097	1,588,226
Intangible assets, net	22,465	22,565
Goodwill	16,937	16,937
Property and equipment, net	92,477	96,018
Operating lease right-of-use assets	70,346	71,182
Restricted cash and cash equivalents, noncurrent	6,428	6,448
Long-term investments	359,724	105,275
Other assets	12,495	12,409
TOTAL ASSETS	1,793,969	1,919,060
CURRENT LIABILITIES:
Accounts payable	7,114	6,334
Accrued and other liabilities	72,260	104,220
Deferred revenue, current	14,694	64,853
Total current liabilities	94,068	175,407
Deferred revenue, noncurrent	1,526	1,526
Operating lease liabilities, noncurrent	109,171	111,673
Contingent consideration, noncurrent	27,610	25,960
Other long-term liabilities	14,238	14,258
TOTAL LIABILITIES	246,613	328,824
Commitments and contingencies (Note 8)
STOCKHOLDERS’ EQUITY:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of March 31, 2024 and December 31, 2023; no shares issued and outstanding as of March 31, 2024 and December 31, 2023	0	0
Common stock, $0.0001 par value; 300,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 135,843,560 and 134,781,286 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	14	13
Additional paid-in capital	1,852,839	1,828,862
Accumulated other comprehensive loss	(2,397)	(815)
Accumulated deficit	(303,100)	(237,824)
TOTAL STOCKHOLDERS’ EQUITY	1,547,356	1,590,236
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 1,793,969	$ 1,919,060

About Vir Biotechnology Inc

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. The company was incorporated in 2016 and is headquartered in San Francisco, California.

CEO	Dr. Marianne De Backer M.B.A., M.Sc., Ph.D.
WEBSITE	vir.bio
INDUSTRY	Biotechnology
EMPLOYEES	576

Vir Biotechnology Inc Frequently Asked Questions

What is the ticker symbol for Vir Biotechnology Inc? What does VIR stand for in stocks?

VIR is the stock ticker symbol of Vir Biotechnology Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Vir Biotechnology Inc (VIR)?

As of Mon May 13 2024, market cap of Vir Biotechnology Inc is 1.33 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VIR stock?

You can check VIR's fair value in chart for subscribers.

What is the fair value of VIR stock?

You can check VIR's fair value in chart for subscribers. The fair value of Vir Biotechnology Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Vir Biotechnology Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VIR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Vir Biotechnology Inc a good stock to buy?

The fair value guage provides a quick view whether VIR is over valued or under valued. Whether Vir Biotechnology Inc is cheap or expensive depends on the assumptions which impact Vir Biotechnology Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VIR.

What is Vir Biotechnology Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon May 13 2024, VIR's PE ratio (Price to Earnings) is -2.47 and Price to Sales (PS) ratio is 16.73. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VIR PE ratio will change depending on the future growth rate expectations of investors.